Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Tissue Adhesions 1Sezary Syndrome 1Polyps 1Pleural Effusion, Malignant 1Myoma 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Endometritis 1Breast Neoplasms 1

Interventions

pembrolizumab 51Ipilimumab 50Cyclophosphamide 43Nivolumab 41aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12spartalizumab 10Radiotherapy 10Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10cobimetinib 9binimetinib 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Melanoma × Doxycycline × Clear all
NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡